Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | P4HB | P07237 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124018 | 1.00 | LMNA (0.62) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL10586039 | 0.89 | LMNA (0.55) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL17061419 | 0.86 | P4HB (0.66) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL12002074 | 0.86 | P4HB (0.66) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL80207 | 0.85 | NPSR1 (0.64) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL15673342 | 0.85 | NPSR1 (0.64) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL29426408 | 0.85 | NPSR1 (0.64) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL80208 | 0.85 | NPSR1 (0.64) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL3167843 | 0.84 | RECQL (0.57) | LMNAMAPTPKMP4HBMEN1 | |
| SCHEMBL1331250 | 0.83 | P4HB (0.62) | LMNAMAPTPKMP4HBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282996-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | claimed |
| WO-2009141782-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-26 | — | — | WO | claimed |
| EP-1067113-B1 | Process for the preparation of phenethylamines and intermediates therefor | LANXESS DEUTSCHLAND GMBH (DE) | 2005-07-20 | — | — | EP | claimed |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2021-12-16 | — | — | US | disclosed |
| EP-1067113-B1 | Process for the preparation of phenethylamines and intermediates therefor | LANXESS DEUTSCHLAND GMBH (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| EP-1453774-A2 | METHOD FOR THE ARYLATION OF OLEFINS | Bayer Aktiengesellschaft (DE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003048079-A2 | METHOD FOR THE ARYLATION OF OLEFINS | BAYER CHEMICALS AG (DE) | 2003-06-12 | — | — | WO | disclosed |
| US-6255528-B1 | REACTING AN ALKYLFLUOROBROMOBENZENE OR FLUOROBROMOBENZENE WITH ACRYLAMIDE IN PRESENCE OF PALLADIUM CATALYST, HYDROGENATING THE RESULTING ARYLACRYLAMIDE, AND THEN REARRANGING IT | LANXESS DEUTSCHLAND GMBH (DE) | 2001-07-03 | — | — | US | disclosed |
| EP-1067113-A2 | Process for the preparation of phenethylamines and intermediates therefor | BAYER AG (DE) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | LMNA 1657/4885MAPT 4580/4885PKM 692/4885 |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | OXA1L, CYP11B2, RORB | LMNA 4001/4885MAPT 4165/4885PKM 897/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | LMNA 1657/4885MAPT 4580/4885PKM 692/4885 |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, NUTF2 | LMNA 1563/4885MAPT 4527/4885PKM 1436/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | LMNA 1563/4885MAPT 4527/4885PKM 1436/4885 |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | ERBB2, EGFR, ERBB3 | LMNA 3652/4885MAPT 1951/4885PKM 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.